Star Scientific, Inc.
Robbins LLP served as lead counsel in this securities fraud class action against Star Scientific, Inc. alleging that the defendants made materially false and misleading statements regarding The Johns Hopkins University School of Medicine’s purported involvement in the clinical development and testing of Star Scientific’s main product – Anatabloc® – to increase Star Scientific’s stock price to the detriment of stockholders and to secure the equity financing the company needed to stay in business. The firm successfully defeated defendants’ motion to dismiss, engaged in extensive settlement discussions and ultimately secured a $5.9 million settlement fund on behalf of stockholders who purchased their shares of Star Scientific stock based on the misrepresentations.
In re Star Scientific, Inc. Securities Litig., No. 3:13-CV-00183-JAG (E.D. Va. July 6, 2015)